Lantern Pharma Inc. (LTRN)

Market Cap	53.82M
Revenue (ttm)	n/a
Net Income (ttm)	-19.88M
Shares Out	10.78M
EPS (ttm)	-1.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	242,073
Open	5.150
Previous Close	5.140
Day's Range	4.850 - 5.280
52-Week Range	2.550 - 6.118
Beta	1.59
Analysts	Strong Buy
Price Target	25.00 (+401.0%)
Earnings Date	Aug 19, 2025

About ALTM

Lantern Pharma Inc. focuses on the discovery and development of oncology drug. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including m...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 11, 2020
• Employees: 24
• Stock Exchange: NASDAQ
• Ticker Symbol: LTRN
• Website: https://www.lanternpharma.com

Analyst Summary

According to one analyst, the rating for LTRN stock is "Strong Buy" and the 12-month stock price target is $25.0.

Price Target

$25.0

(401.00% upside)

Analyst Consensus: Strong Buy